My ePortfolio Register   

Duration of checkpoint inhibitor therapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.05.17
Views: 1048

Prof Dirk Schadendorf - University of Duisburg-Essen, Essen, Germany

Dr Schadendorf speaks with ecancer at EADO 2017 about objective response as a possible milestone for the administration of checkpoint immunotherapy.

Taking current ipilimumab protocols as an example, he considers how long PD1 antibodies might be administered to achieve maximum clinical benefit.

Based on data from KEYNOTE-001, Dr Schadendorf questions that patients who achieve complete response may be primed, or sensitive, to other immune therapies should they relapse.

In Checkmate 69 and 67, combined ipilumumab and nivolumab resulted in nearly half of patients discontinuing due to toxicity, but there was little difference in PFS and response rate between those completing their course and those ceasing early, leading Dr Schadendorf to consider how long these potentially toxic courses are required for significant benefit.

He goes on to consider the wider trial designs and health-care provider stakes in drug discontinuation.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence